A Phase 2, Parallel Group, Randomized, Double- Blind, Placebo-Controlled, 3-Arm, Multicenter Treatment Study to Evaluate the Efficacy and Safety of GSK4527226 [AL101] Intravenous Infusion Compared With Placebo in Patients With Early Alzheimer's Disease
Latest Information Update: 30 Apr 2025
At a glance
- Drugs AL 101 Alector/Adimab (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Acronyms PROGRESS-AD
- Sponsors GSK
Most Recent Events
- 08 Apr 2025 Planned End Date changed from 16 Nov 2026 to 23 Nov 2026.
- 08 Apr 2025 Planned primary completion date changed from 16 Nov 2026 to 23 Nov 2026.
- 08 Apr 2025 Status changed from recruiting to active, no longer recruiting.